Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
World game at war: why some European nations have threatened a World Cup boycott 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
BOSTON, May 07, 2018 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update.
To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (international) and refer to conference ID: 4076397. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
[email protected]
